FT Options’s Achillion Pharmaceuticals ACHN Stock Holding History

FT Options’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-30,000	Closed	-$232K	–	432
2016 Q1	$232K	Buy	+30,000	New	+$220K	0.24%	75

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FT Options's ACHN Position: Q2 2016 in Review

FT Options sold out of Achillion Pharmaceuticals (ACHN) in Q2 2016, closing a stake of 30,000 shares — an estimated $232K sold.

FT Options first reported a position in ACHN in Q1 2016 and held it in 1 quarter. The position peaked at $232K in Q1 2016. 147 funds tracked by Wall St. Rank hold ACHN as of Q2 2016.

FT Options reported no remaining Achillion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
FT Options sold 30,000 Achillion Pharmaceuticals shares in Q2 2016, an estimated $232K.
FT Options first reported a position in Achillion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
FT Options's Achillion Pharmaceuticals position peaked at $232K in Q1 2016.
147 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2016.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.